secwatch.observer — SEC 8-K summary
======================================

Issuer:     INCYTE CORP (INCY)
CIK:        0000879169
Form:       8-K
Filed at:   2023-02-07T23:59:59+00:00
Accession:  0000879169-23-000005
Event type: earnings
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Incyte reports FY2022 revenue $3.4B (+14%); Jakafi up 13%; provides 2023 guidance
--------------------------------------------------------------------------------

- FY2022 total revenues $3.39B (+14% YoY), net product rev $2.75B (+18%); GAAP diluted EPS $1.52, non-GAAP $2.78.
- Jakafi net rev Q4 $647M (+9%), FY $2.41B (+13%); 2023 guidance range $2.53–2.63B.
- Opzelura net rev Q4 $61M, FY $129M driven by atopic dermatitis and vitiligo launch; patent extended to 2040.
- GAAP net income $341M (vs $949M in 2021, which included a large tax benefit); cash & securities $3.2B.
- 2023 guidance: Jakafi $2.53–2.63B; R&D $1.61–1.65B GAAP; SG&A $1.05–1.15B GAAP.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/879169/000087916923000005/0000879169-23-000005-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/879169/000087916923000005/incy-20230207.htm
  HTML page:      https://secwatch.observer/filing/0000879169-23-000005

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer